Recent Press Releases

FDA approves new combination vaccine that protects children against two bacterial diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria...

GSK receives FDA approval for MenHibrix

GSK receives FDA approval for MenHibrix Issued: Thursday 14 June 2012, Philadelphia, Pennsylvania First combination vaccine to help prevent meningococcal serogroups C and Y and Hib disease...

Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study

PRINCETON, N.J., Jun 13, 2012-- Advaxis, Inc., ADXS -1.06% , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of...

Clinical Trial of Human Hookworm Vaccine Begins at Children's National Medical Center

Clinical Trial of Human Hookworm Vaccine Begins at Children's National Medical Center June 13, 2012 WASHINGTON, D.C.—June 13, 2012—Today, the Sabin Vaccine Institute, in partnership with...

Cocaine vaccine gets a boost with molecular imaging

Cocaine vaccine gets a boost with molecular imaging PET imaging studies reveal how an inoculation against cocaine addiction uses the body's own immune system to prevent a high 11-Jun-2012 Miami...

Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study

Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study PRINCETON, N.J., Jun 13, 2012 (BUSINESS WIRE) -- Advaxis, Inc., a leader in developing the next...

Genocea Announces New Research Identifying Potential Vaccine Candidates for Chlamydia

Genocea Announces New Research Identifying Potential Vaccine Candidates for Chlamydia -- Study published in Vaccine demonstrates antigens capable of eliciting immune responses that provide protection...

'Hitch-hiking' viral therapy deals a double blow to cancer

'Hitch-hiking' viral therapy deals a double blow to cancer 13th June 12 Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumours undetected by...

VaxInnate Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu

VaxInnate Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu CRANBURY, NJ, June 12, 2012 – VaxInnate Corporation today announced that enrollment has...

OPKO Health To Acquire Stake in Israeli Hepatitis B Vaccine Manufacturer

MIAMI, Jun 05, 2012-- OPKO Health, Inc. has entered into a definitive agreement to acquire a forty-five percent stake in a private Israeli company that produces a third-generation hepatitis B vaccine...

Immunovaccine's DPX-0907 Demonstrates Ability to Generate Promising Immune Reponses in Multiple Cancers in a Clinical Trial Presented at ASCO Annual Meeting

Halifax, Nova Scotia; June 4, 2012 – Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX-V: IMV), a clinical stage vaccine company, today announced positive results from a Phase I...

Potential New HIV Vaccine/Therapy Target

(May 30, 2012) — After being infected with simian immunodeficiency virus (SIV) in a laboratory study, rhesus macaques that had more of a certain type of immune cell in their gut than others had...

Generex Announces Presentation of New Immune Response Data from AE37 Phase II Breast Cancer Trial at ASCO 2012

Generex Announces Presentation of New Immune Response Data from AE37 Phase II Breast Cancer Trial at ASCO 2012 WORCESTER, Mass. and TORONTO, June 5, 2012 /PRNewswire/ -- Generex Biotechnology...

Ventria Bioscience's InVitria Division Awarded 2-Year, $1.5 Million Grant to Develop Superior System for Cell-Based Vaccine Production

Ventria Bioscience's InVitria Division Awarded 2-Year, $1.5 Million Grant to Develop Superior System for Cell-Based Vaccine Production June 4, 2012 FORT COLLINS, Colo.--(BUSINESS WIRE)-- Ventria...

Jennerex Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting

Jennerex Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting CHICAGO, June 4, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics...

Galena Biopharma Announces NeuVax(TM) (E75) Improves Disease-Free Survival at 60-Month Median Follow-Up

Galena Biopharma Announces NeuVax(TM) (E75) Improves Disease-Free Survival at 60-Month Median Follow-Up - The combined SN-33 (Node Positive) (n=97) and SN-34 (Node Negative) (n=90)...

Galena Biopharma Presents NeuVax Phase 1/2 Boosters Improve Disease-Free Survival at 60-Month Median Follow-Up

Galena Biopharma Presents NeuVax Phase 1/2 Boosters Improve Disease-Free Survival at 60-Month Median Follow-Up - Booster inoculations are well-tolerated and appear to maintain long-term...

NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer

NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients With Non-Small Cell Lung Cancer AMES, Iowa, June 4,...

NewLink Genetics Reports Two- and Three-Year Overall Survival Data From Its Phase-2 HyperAcute® Pancreas (algenpantucel-L) Immunotherapy Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

NewLink Genetics Reports Two- and Three-Year Overall Survival Data From Its Phase-2 HyperAcute® Pancreas (algenpantucel-L) Immunotherapy Trial at the American Society of Clinical Oncology (ASCO)...

Interim Analysis for Bavarian Nordic's Phase 2 PROSTVAC® Trial Presented at Annual ASCO Meeting

Interim Analysis for Bavarian Nordic's Phase 2 PROSTVAC® Trial Presented at Annual ASCO Meeting KVISTGAARD, Denmark, June 2, 2012 - Bavarian Nordic A/S (OMX: BAVA) today announces new interim...